中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2012年
30期
17-20
,共4页
方文雄%朱敏%周晓秋%叶梁%林云珍
方文雄%硃敏%週曉鞦%葉樑%林雲珍
방문웅%주민%주효추%협량%림운진
肺疾病,慢性阻塞性%沙美特罗氟替卡松%异丙托溴铵
肺疾病,慢性阻塞性%沙美特囉氟替卡鬆%異丙託溴銨
폐질병,만성조새성%사미특라불체잡송%이병탁추안
Pulmonary disease,chronic obstructive%Salmeterol xinafoate and fluticasone propionate%Ipratropium bromide aerosol
目的 评估沙美特罗氟替卡松联合异丙托溴铵气雾剂对慢性阻塞性肺疾病(COPD)稳定期患者BODE指数的影响.方法 将120例COPD稳定期患者按随机数字表法分为对照组与观察组,每组60例.对照组患者接受异丙托溴铵雾化吸入,观察组接受沙美特罗氟替卡松联合异丙托溴铵吸入,疗程6个月.比较两组治疗前后的BODE指数、SGRQ问卷分数及血浆皮质醇、骨密度的变化.结果 两组治疗前BODE指数总分比较差异无统计学意义(P＞0.05)；观察组治疗后BODE指数中呼吸困难量表评级、第1秒用力呼气容积占预计值百分比、6 min步行试验距离、BODE指数总分均显著优于对照组[(1.9±0.5)级比(2.3±0.5)级、(58.5±7.3)％比(50.4±6.2)％、(411.1 ±56.8)m比(347.5±60.4)m、(3.3±1.0)分比(3.8±1.3)分],差异有统计学意义(P＜0.05).两组治疗前SGRQ评分比较差异无统计学意义(P＞ 0.05),观察组治疗后SGRQ呼吸症状、活动受限及疾病影响各项及总分均显著优于对照组[(20.7±10.3)分比(37.9±14.4)分、(20.7±9.5)分比(34.8±13.0)分、(16.3±6.7)分比(27.2±11.8)分、(17.5±7.0)分比(34.6±12.3)分],差异有统计学意义(P＜0.01).两组治疗前后血浆皮质醇、骨密度比较差异无统计学意义(P＞0.05).结论 沙美特罗氟替卡松联合异丙托溴铵吸入治疗COPD稳定期患者可显著改善患者肺功能,提高生活质量,不良反应少.
目的 評估沙美特囉氟替卡鬆聯閤異丙託溴銨氣霧劑對慢性阻塞性肺疾病(COPD)穩定期患者BODE指數的影響.方法 將120例COPD穩定期患者按隨機數字錶法分為對照組與觀察組,每組60例.對照組患者接受異丙託溴銨霧化吸入,觀察組接受沙美特囉氟替卡鬆聯閤異丙託溴銨吸入,療程6箇月.比較兩組治療前後的BODE指數、SGRQ問捲分數及血漿皮質醇、骨密度的變化.結果 兩組治療前BODE指數總分比較差異無統計學意義(P＞0.05)；觀察組治療後BODE指數中呼吸睏難量錶評級、第1秒用力呼氣容積佔預計值百分比、6 min步行試驗距離、BODE指數總分均顯著優于對照組[(1.9±0.5)級比(2.3±0.5)級、(58.5±7.3)％比(50.4±6.2)％、(411.1 ±56.8)m比(347.5±60.4)m、(3.3±1.0)分比(3.8±1.3)分],差異有統計學意義(P＜0.05).兩組治療前SGRQ評分比較差異無統計學意義(P＞ 0.05),觀察組治療後SGRQ呼吸癥狀、活動受限及疾病影響各項及總分均顯著優于對照組[(20.7±10.3)分比(37.9±14.4)分、(20.7±9.5)分比(34.8±13.0)分、(16.3±6.7)分比(27.2±11.8)分、(17.5±7.0)分比(34.6±12.3)分],差異有統計學意義(P＜0.01).兩組治療前後血漿皮質醇、骨密度比較差異無統計學意義(P＞0.05).結論 沙美特囉氟替卡鬆聯閤異丙託溴銨吸入治療COPD穩定期患者可顯著改善患者肺功能,提高生活質量,不良反應少.
목적 평고사미특라불체잡송연합이병탁추안기무제대만성조새성폐질병(COPD)은정기환자BODE지수적영향.방법 장120례COPD은정기환자안수궤수자표법분위대조조여관찰조,매조60례.대조조환자접수이병탁추안무화흡입,관찰조접수사미특라불체잡송연합이병탁추안흡입,료정6개월.비교량조치료전후적BODE지수、SGRQ문권분수급혈장피질순、골밀도적변화.결과 량조치료전BODE지수총분비교차이무통계학의의(P＞0.05)；관찰조치료후BODE지수중호흡곤난량표평급、제1초용력호기용적점예계치백분비、6 min보행시험거리、BODE지수총분균현저우우대조조[(1.9±0.5)급비(2.3±0.5)급、(58.5±7.3)％비(50.4±6.2)％、(411.1 ±56.8)m비(347.5±60.4)m、(3.3±1.0)분비(3.8±1.3)분],차이유통계학의의(P＜0.05).량조치료전SGRQ평분비교차이무통계학의의(P＞ 0.05),관찰조치료후SGRQ호흡증상、활동수한급질병영향각항급총분균현저우우대조조[(20.7±10.3)분비(37.9±14.4)분、(20.7±9.5)분비(34.8±13.0)분、(16.3±6.7)분비(27.2±11.8)분、(17.5±7.0)분비(34.6±12.3)분],차이유통계학의의(P＜0.01).량조치료전후혈장피질순、골밀도비교차이무통계학의의(P＞0.05).결론 사미특라불체잡송연합이병탁추안흡입치료COPD은정기환자가현저개선환자폐공능,제고생활질량,불량반응소.
Objective To evaluate the clinical effect of salmeterol xinafoate and fluticasone propionate powder for inhalation combined ipratropium bromide aerosol in patients with stable chronic obstructive pulmonary disease (COPD).Methods One hundred and twenty patients with stable COPD was randomly divided into control group and observation group with 60 patients each.The control group was received ipratropium bromide aerosol inhalation,and the observation group was given salmeterol xinafoate and fluticasone propionate powder for inhalation and ipratropium bromide aerosol for 6 months.BODE index,SGRQ scores,plasma cortisol and bone mineral density were compared between two groups before and after treatment.Results BODE index scores had no significant difference between two groups before treatment (P＞0.05).After treatment,BODE index scores,dyspnea scale,FEV1％,6MWD and BODE index total scores in observation group were superior to those in control group [ (1.9 ± 0.5) grades vs. (2.3 ± 0.5)grades,(58.5 ± 7.3)％ vs.(50.4 ± 6.2)％,(411.1 ± 56.8) m vs.(347.5 ± 60.4) m,(3.3 ± 1.0) scores vs.(3.8 ± 1.3 ) scores ],there were significant differences (P＜0.05 ).SGRQ scores had no significant difference between two groups before treatment (P＞0.05 ).After treatment and in SGRQ scores,respiration symptom,limitation of activity,disease influence scores in observation group were significantly lower than those in control group [ (20.7 ± 10.3 ) scores vs.(37.9 ± 14.4) scores,(20.7 ± 9.5 ) scores vs.(34.8 ± 13.0) scores,(16.3 ± 6.7) scores vs.(27.2 ± 11.8) scores,(17.5 ± 7.0) scores vs. (34.6 ± 12.3) scores],there were signiticant differences (P＜0.01 ).There were no significant difference of plasma cortisol and bone mineral density between two groups (P＞0.05).Conclusions Salmeterol xinafoate and fluticasone propionate powder for inhalation and ipratropium bromide aerosol in patients with stable COPD can greatly improve the lung function and life quality and with less adverse reaction.
